TSE:TR - Trillium Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseC$29.80Today's RangeC$29.65 - C$30.2252-Week RangeC$28.50 - C$39.45Volume49,075 shsAverage Volume99,071 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Receive TR News and Ratings via Email Sign-up to receive the latest news and ratings for TR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolTSE:TR Previous Symbol CUSIPN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapC$0.00 OptionableOptionable Trillium Therapeutics (TSE:TR) Frequently Asked Questions What is Trillium Therapeutics' stock symbol? Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR." How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc (TSE:TR) released its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.87) by $0.04. View Trillium Therapeutics' Earnings History. When is Trillium Therapeutics' next earnings date? Trillium Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for Trillium Therapeutics. What is the consensus analysts' recommendation for Trillium Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics. Has Trillium Therapeutics been receiving favorable news coverage? Media stories about TR stock have been trending somewhat positive on Friday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trillium Therapeutics earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are Trillium Therapeutics' key executives? Trillium Therapeutics' management team includes the folowing people: Calvin R. Stiller M.D., Independent Chairman of the BoardNiclas Stiernholm, President, Chief Executive Officer, DirectorJames T. Parsons, Chief Financial OfficerMalik Slassi, Senior Vice President - Discovery ResearchRobert Uger, Chief Scientific OfficerScott Duncan, Director of Intellectual PropertyPenka Petrova, Chief Development OfficerEric L Sievers, Chief Medical OfficerLuke M. Beshar CPA, Independent Director (Age 59)Henry Friesen M.D., Independent Director (Age 79) How do I buy shares of Trillium Therapeutics? Shares of TR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Trillium Therapeutics' official website? The official website for Trillium Therapeutics is http://www.trilliumtherapeutics.com/. How can I contact Trillium Therapeutics? Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627. MarketBeat Community Rating for Trillium Therapeutics (TSE TR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 74 (Vote Outperform)Underperform Votes: 54 (Vote Underperform)Total Votes: 128MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is Cost of Capital?